Interference of the IGF system as a strategy to inhibit breast cancer growth

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Experimental evidence suggests that human breast cancer cells can be regulated by the IGF-I and IGF-II present in the tumor stromal elements and/or by the endogenous tumor cell IGF-II in a paracrine or autocrine fashion. Thus, blockade of the receptor signalling pathway could lead to diminished tumor growth. Blockade of the type I IGF receptor by a monoclonal antibody (αIR3) has been used as a strategy to demonstrate the importance of the IGF pathway. Although αIR3 could not block serum-free growth of breast cancer cell lines, it could inhibit anchorage independent growth in most cell lines in the presence of serum. In vivo, αIR3 administered at the time of tumor cell inoculation could inhibit MDA-MB-231 tumor formation in athymic mice; however, inhibition of established tumors was not seen. Moreover, αIR3 could not inhibit tumor formation of the MCF-7 cell line in vivo. These results suggest that blockade of the type I IGF receptor can inhibit the growth of some breast cancer cells both in vitro and in vivo. Future anti-growth factor strategies include the combination of anti-IGF receptor antibodies with IGF neutralizing modalities, the dual blockade of growth factor receptors (epidermal growth factor receptor and type I IGF receptor), and combinations of steroid hormone antagonists and anti-growth factor treatments to maximize tumor inhibition.

Original languageEnglish (US)
Pages (from-to)101-106
Number of pages6
JournalBreast Cancer Research and Treatment
Volume22
Issue number1
DOIs
StatePublished - Feb 1 1992

Fingerprint

Breast Neoplasms
Growth
IGF Type 1 Receptor
Neoplasms
Insulin-Like Growth Factor II
Cell Line
Intercellular Signaling Peptides and Proteins
Hormone Antagonists
Growth Factor Receptors
MCF-7 Cells
Serum
Insulin-Like Growth Factor I
Epidermal Growth Factor Receptor
Nude Mice
Steroids
Monoclonal Antibodies
Antibodies

Keywords

  • anti-IGF-receptor antibodies
  • autocrine growth regulation
  • breast cancer cells
  • growth inhibition
  • IGF receptors
  • IGF-I
  • IGF-II
  • paracrine growth regulation
  • therapeutic modalities

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Interference of the IGF system as a strategy to inhibit breast cancer growth. / Arteaga, Carlos L.

In: Breast Cancer Research and Treatment, Vol. 22, No. 1, 01.02.1992, p. 101-106.

Research output: Contribution to journalArticle

@article{5808467b5090402db9ddb77a68c2e913,
title = "Interference of the IGF system as a strategy to inhibit breast cancer growth",
abstract = "Experimental evidence suggests that human breast cancer cells can be regulated by the IGF-I and IGF-II present in the tumor stromal elements and/or by the endogenous tumor cell IGF-II in a paracrine or autocrine fashion. Thus, blockade of the receptor signalling pathway could lead to diminished tumor growth. Blockade of the type I IGF receptor by a monoclonal antibody (αIR3) has been used as a strategy to demonstrate the importance of the IGF pathway. Although αIR3 could not block serum-free growth of breast cancer cell lines, it could inhibit anchorage independent growth in most cell lines in the presence of serum. In vivo, αIR3 administered at the time of tumor cell inoculation could inhibit MDA-MB-231 tumor formation in athymic mice; however, inhibition of established tumors was not seen. Moreover, αIR3 could not inhibit tumor formation of the MCF-7 cell line in vivo. These results suggest that blockade of the type I IGF receptor can inhibit the growth of some breast cancer cells both in vitro and in vivo. Future anti-growth factor strategies include the combination of anti-IGF receptor antibodies with IGF neutralizing modalities, the dual blockade of growth factor receptors (epidermal growth factor receptor and type I IGF receptor), and combinations of steroid hormone antagonists and anti-growth factor treatments to maximize tumor inhibition.",
keywords = "anti-IGF-receptor antibodies, autocrine growth regulation, breast cancer cells, growth inhibition, IGF receptors, IGF-I, IGF-II, paracrine growth regulation, therapeutic modalities",
author = "Arteaga, {Carlos L.}",
year = "1992",
month = "2",
day = "1",
doi = "10.1007/BF01833338",
language = "English (US)",
volume = "22",
pages = "101--106",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Interference of the IGF system as a strategy to inhibit breast cancer growth

AU - Arteaga, Carlos L.

PY - 1992/2/1

Y1 - 1992/2/1

N2 - Experimental evidence suggests that human breast cancer cells can be regulated by the IGF-I and IGF-II present in the tumor stromal elements and/or by the endogenous tumor cell IGF-II in a paracrine or autocrine fashion. Thus, blockade of the receptor signalling pathway could lead to diminished tumor growth. Blockade of the type I IGF receptor by a monoclonal antibody (αIR3) has been used as a strategy to demonstrate the importance of the IGF pathway. Although αIR3 could not block serum-free growth of breast cancer cell lines, it could inhibit anchorage independent growth in most cell lines in the presence of serum. In vivo, αIR3 administered at the time of tumor cell inoculation could inhibit MDA-MB-231 tumor formation in athymic mice; however, inhibition of established tumors was not seen. Moreover, αIR3 could not inhibit tumor formation of the MCF-7 cell line in vivo. These results suggest that blockade of the type I IGF receptor can inhibit the growth of some breast cancer cells both in vitro and in vivo. Future anti-growth factor strategies include the combination of anti-IGF receptor antibodies with IGF neutralizing modalities, the dual blockade of growth factor receptors (epidermal growth factor receptor and type I IGF receptor), and combinations of steroid hormone antagonists and anti-growth factor treatments to maximize tumor inhibition.

AB - Experimental evidence suggests that human breast cancer cells can be regulated by the IGF-I and IGF-II present in the tumor stromal elements and/or by the endogenous tumor cell IGF-II in a paracrine or autocrine fashion. Thus, blockade of the receptor signalling pathway could lead to diminished tumor growth. Blockade of the type I IGF receptor by a monoclonal antibody (αIR3) has been used as a strategy to demonstrate the importance of the IGF pathway. Although αIR3 could not block serum-free growth of breast cancer cell lines, it could inhibit anchorage independent growth in most cell lines in the presence of serum. In vivo, αIR3 administered at the time of tumor cell inoculation could inhibit MDA-MB-231 tumor formation in athymic mice; however, inhibition of established tumors was not seen. Moreover, αIR3 could not inhibit tumor formation of the MCF-7 cell line in vivo. These results suggest that blockade of the type I IGF receptor can inhibit the growth of some breast cancer cells both in vitro and in vivo. Future anti-growth factor strategies include the combination of anti-IGF receptor antibodies with IGF neutralizing modalities, the dual blockade of growth factor receptors (epidermal growth factor receptor and type I IGF receptor), and combinations of steroid hormone antagonists and anti-growth factor treatments to maximize tumor inhibition.

KW - anti-IGF-receptor antibodies

KW - autocrine growth regulation

KW - breast cancer cells

KW - growth inhibition

KW - IGF receptors

KW - IGF-I

KW - IGF-II

KW - paracrine growth regulation

KW - therapeutic modalities

UR - http://www.scopus.com/inward/record.url?scp=0026714984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026714984&partnerID=8YFLogxK

U2 - 10.1007/BF01833338

DO - 10.1007/BF01833338

M3 - Article

C2 - 1421419

AN - SCOPUS:0026714984

VL - 22

SP - 101

EP - 106

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -